AzTrials
AzTrials

Healthy VolunteersULTRAFASTECHONCT01096264

Non-Invasive Quantitative Imaging of Human Local Arterial Wall Elasticity Using Supersonic Shear Imaging

A study testing SSI and SphygmoCor® evaluations in people with Healthy Volunteers and Vascular Ehlers Danlos Syndrome, run by French Cardiology Society at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Arterial stiffness is associated with increased risk of cardiovascular events and death. Most of existing technique need dedicated device for arterial stiffness evaluation and indirect calculation of intra arterial pressure. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
What is being tested?
SSI and SphygmoCor® evaluations
Could I receive a placebo?
No, everyone receives an active treatment
How many people
145 participants
Where
1 siteFrance
Study dates
Mar 2010to Mar 2011
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy volunteers between 18 and 70 years old of two sexes.
  • Caucasian origin
  • No tobacco or stopped for more than 5 years
  • BMI between 18 and 30 kg/m2.
  • Blood pressure after 5 minutes of rest < 140 and 90 mmHg.
  • Biological test (haematological biochemistry test in blood , urine test and toxicology tests are all normal) ECG, Blood pressure and Heart rhythm normal.
Show all 20Show fewer
  • All volunteers received information on the research and signed the consent form.
  • Health system protection required
  • Age between, 18 et 70 years old for the two sexes
  • Presence of two major criteria of Villefranche classification (Am J Med Genet 1998 ;77:31-7) and/or heterozygote pathogen mutation of COL3A1 gene.
  • At least 4cm long normal arterial segment (carotid or femoral) analyzed by mode B echograph.
  • All patient received information on the research and signed the consent form.
  • Health system protection required
  • General Exclusion Criteria :
  • Pregnancy
  • Echograph gel allergy
  • Local Artery disease (dissection or thrombosis)
  • Arrhythmia
  • No health insurance coverage
  • Incapacity or refused to sign the consent form

Who cannot join

  • Acute or Chronic Systemic disease (atherosclerosis)
  • Alcohol abuse or drug abuse (cocaine,cannabis,etc..)
  • Active or past tobacco
  • Hypercholesterolemia (LDLc >1.09 g/l)
  • Exclusion period according to the national record for volunteer of clinical trial.
  • No intact (carotid or femoral) segment for SSI analysis
  • AT2 inhibitors or Beta blockers treatment will be notified but are not considered as exclusion criteria.

Trial locations and contacts

1 site in 1 country.

France1 site
  • CIC - Hôpital Européen Georges Pompidou

    Paris, 75015

Other trials in France

About this study

Official title: Establishment of Local Arterial Stiffness Normal Values (Carotid and Femoral) on Healthy Volunteers Using Supersonic Shear Imaging

Arterial stiffness is associated with increased risk of cardiovascular events and death.

Most of existing technique need dedicated device for arterial stiffness evaluation and indirect calculation of intra arterial pressure. Supersonic Shear Imaging (SSI) is a novel non-invasive technique based on remote palpation of biological tissues that can image with very high temporal resolution (up to 10,000 images/s) and quantify the local viscoelastic properties of tissues. The investigators goal was to apply this SSI technique for arterial stiffness evaluation and local pulse wave velocity (PWV) calculation.

As a first step, the primary goal of this study is to establish normal values of local pulse wave velocity and arterial stiffness (carotid and femoral) by SSI on hundred healthy volunteers.

Read the detailed description

Provide a more extensive description, if desired. Avoid duplication of information to be recorded elsewhere, such as eligibility criteria or outcome measures.

Being tested
SSI and SphygmoCor® evaluations
Keywords
Arterial stiffness, Pulse wave velocity, Ultrafastecho, Supersonic shear imaging
Medical subject headings
Ehlers-Danlos Syndrome, Type IV

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SSI and SphygmoCor® evaluationsOther

    • SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.
    • SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived.
Study groups in NCT01096264
Study groupRoleWhat they receive
Healthy volunteerOtherHealthy volunteer undergoing two imagery evaluation : * SSI technique for local PWV and arterial stiffness evaluation * SphygmoCor® for aortic PWV.
Receives: Other: SSI and SphygmoCor® evaluations
vEDS patientsOthervEDS patients undergoing two imagery evaluations: * SSI technique for local PWV and arterial stiffness evaluation * SphygmoCor® for aortic PWV.
Receives: Other: SSI and SphygmoCor® evaluations

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Normal Values by SSI

    Normal Values by SSI of local PWV and arterial wall stiffness(carotid and femoral).

    Measured: day one

Secondary outcomes (3)
  1. repeatability of the "primary outcome measure"

    Evaluation of the repeatability of the "primary outcome measure" on 100 healthy volunteers and 30 patients with Vascular Ehlers Danlos Syndrome (vEDS).

    Measured: Day one

  2. Comparison between 2 populations of values by SSI

    Comparison between healthy volunteers and vEDS patients for PWV and arterial stiffness evaluated by SSI.

    Measured: Day one

  3. Comparison of values between SSI and standard gold

    Concordance evaluation between PWV calculated by SSI and Aortic Pulse wave velocity calculated by ShygmoCor®

    Measured: Day one

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Mar 2010 (estimated)
  2. Study startMar 2010
  3. Primary completionMar 2011
  4. Study completionMar 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Non-randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
145 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01096264
Sponsor's protocol ID
2009-03
Acronym
ULTRAFASTECHO
Status last verified
Mar 2015
First submitted
19 Mar 2010
Last updated
9 Mar 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing SSI and SphygmoCor® evaluations in people with Healthy Volunteers and Vascular Ehlers Danlos Syndrome, run by French Cardiology Society at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Normal Values by SSI (time frame: day one). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in